

Golden Retriever's Quality of Life Restored after Treatment with VetStem Cell Therapy for Hip Osteoarthritis

Isabella, a golden retriever, has a restored quality of life after treatment with VetStem Cell Therapy for bilateral hip arthritis.

POWAY, CA, UNITED STATES, July 13, 2021 /EINPresswire.com/ -- Isabella, or Izzy for short, is a golden retriever that was diagnosed with severe bilateral hip osteoarthritis as a result of hip dysplasia when she was approximately three years old. Izzy was experiencing lameness in her back end and her owners took her to an orthopedic surgeon to explore all possible treatment options. After ruling out total hip replacement, her owners opted to have Izzy treated with VetStem Cell Therapy.



To begin the process, Izzy's veterinarian collected fat tissue from her abdomen during a minimally invasive anesthetic procedure. Once collected, the fat was aseptically packaged and



I would offer this treatment again in a heartbeat"

Izzy's Mom

shipped to the VetStem laboratory in Poway, California. VetStem lab technicians processed the fat to extract and concentrate the stem and regenerative cells contained therein and three stem cell injections were shipped to Izzy's veterinarian for treatment. Approximately 48 hours after the initial fat collection procedure, Izzy received an

injection of her own stem cells into each hip as well as intravenously.

In addition to VetStem Cell Therapy, Izzy received treatment with Veterinary Platelet Enhancement Therapy (V-PET™). V-PET is a tool used by veterinarians to concentrate an animal's platelets and other healing cells from a sample of their own blood. The process is quick and relatively easy and is performed right there in the veterinary hospital. Platelet therapy can work synergistically with stem cell therapy to improve and expedite healing.

According to her owners, Izzy responded well to the stem cell and platelet therapies. Her owners reported that the outcome exceeded their expectations stating, "Her quality of life has been restored and she's an energetic, active and life-loving golden retriever. I would offer this treatment again in a heartbeat, especially to younger, otherwise healthy dogs. Thank you for making this treatment available, it has truly been a game changer for us. She got her life back!!!"

Unfortunately, many dogs suffer from joint dysplasia which can lead to painful osteoarthritis. Pain associated with osteoarthritis can greatly reduce a dog's quality of life. According to surveys answered by owners and veterinarians, greater than 80% of dogs showed an improved quality of life after receiving VetStem Cell Therapy for orthopedic conditions. A peer-reviewed study of dogs with chronic osteoarthritis of the hip found that stem cells reduced pain and lameness. Stem cells are regenerative cells that can differentiate into many tissue types, reduce pain and inflammation, help to restore range of motion, and stimulate regeneration of tendon, ligament, and joint tissues.

About VetStem Biopharma, Inc.

VetStem Biopharma is a veterinarian-led Company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego, California, currently offers veterinarians an autologous stem cell processing service (from patients' own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 15 years and thousands of treatments by veterinarians for joint, tendon and ligament issues, VetStem has made regenerative medicine applications a therapeutic reality. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. In addition to its own portfolio of patents, VetStem holds exclusive global veterinary licenses to a large portfolio of issued patents in the field of regenerative medicine.

Kristi Hauta VetStem Biopharma +1 858-748-2004 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/546073994

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.